References
- Clandinin MTJJ. Fatty acid metabolism in brain in relation to development, membrane structure and signalling. Handbook of essential fatty acid biology, biochemistry and behavioural neurobiology, DI Mostofsky, S Yehuda. Humana Press, TotowaNew Jersey 1997
- Das UN. Long-chain polyunsaturated fatty acids metabolism, physiology and clinical significance. A perinatal strategy for preventing adult disease: The role of long-chain polyunsaturated fatty acids, UN Das. Kluwer Academic Publishers, BostonDordrecht, London 2002
- Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: Randomised double-blind placebo-controlled study. British Journal of Psychiatry 2006; 188: 46–50
- Gesch CB, Hammond SM, Hampson SE, Eves A, Crowder MJ. Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Randomised, placebo-controlled trial. British Journal of Psychiatry 2002; 181: 22–28
- Haag M. Essential fatty acids and the brain. Canadian Journal Psychiatry 2003; 48: 195–203
- Halsted CH. Dietary supplements and the American Journal of Clinical Nutrition (1). American Journal of Clinical Nutrition 2000; 71: 399–400
- Hargreaves KM, Clandinin MT. Dietary control of diacylphosphatidylethanolamine species in brain. Biochimica et Biophysica Acta 1988; 962: 98–104
- Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequently sampled intravenous glucose tolerance test and minimal model analysis. Archives of General Psychiatry 2005; 62: 19–28
- Horrobin DF. The phospholipid concept of psychiatric disorders and its relationship to the neurodevelopmental concept of schizophrenia. Phospholipid spectrum disorder in psychiatry, M Peet, I Glen, DF Horrobin. Marius Press, Lancashire, UK 1999; 3–20
- Horrobin DF, Glen AI, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophrenia Research 1994; 13: 195–207
- Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Systematic Review. 2003, CD001257
- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005; 353: 1209–1223
- McGahon B, Lynch MA. The synergism between metabotropic glutamate receptor activation and arachidonic acid on glutamate release is occluded by induction of long-term potentiation in the dentate gyrus. Neuroscience 1996; 72: 847–855
- Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, et al. Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial. Neurology 2005; 65: 286–292
- Sastry PS. Lipids of nervous tissue: Composition and metabolism. Progress in Lipid Research 1985; 24: 69–176
- Tence M, Murphy N, Cordier J, Premont J, Glowinski J. Synergistic effects of acetylcholine and glutamate on the release of arachidonic acid from cultured striatal neurons. Journal of Neurochemistry 1995; 64: 1605–1613
- Vaddadi K. Eicosanoid precursors in the treatment of Huntington's disease. The Eicosanoids, P Curtis-Prior. Wiley, Chichester 2004; 499–506
- Vaddadi KS, Courtney P, Gilleard CJ, Manku MS, Horrobin DF. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Research 1989; 27: 313–323
- van Dellen A, Hannan AJ. Genetic and environmental factors in the pathogenesis of Huntington's disease. Neurogenetics 2004; 5: 9–17